
    
      Eligibility for participation of this study will be determined from demographic information,
      medical history, physical examination, electrocardiogram(ECG) and clinical laboratory tests
      within 3 weeks before study drug administration. Subjects suitable for this study will be
      admitted to the Clinical Trials Center, Seoul National University Hospital on the day before
      dosing, and they will be overnight-fasted from 9 p.m. of Day -1. Urine collection is
      scheduled from 24 hours before midazolam administration to 24 hours after administration.
      Subjects will be dosed midazolam by intravenous around at 9 a.m. of Day 1. Subjects will
      perform scheduled procedures including clinical laboratory tests, electrocardiograms and
      pharmacokinetic samplings. Subjects will be discharged on Day 2 and visit the Clinical Trials
      Center for period 2, ketoconazole administration. After 3 days of ketoconazole
      administration, midazolam will be dosed with ketoconazole on Day 4 of period 2. Subjects will
      perform scheduled procedure and on period 3 rifampicin will be dosed for 9 days and on Day 10
      of period 3 midazolam will be dosed with rifampicin. After subjects perform scheduled
      procedure, the study will be terminated 6-8 days after the end of period 3.
    
  